Soligenix, Inc. (NasdaqCM:SNGX) is looking for acquisitions. Christopher J. Schaber, PhD, President and Chief Executive Officer said, 'With approximately $10.3 million in cash at September 30, 2023, not including our non-dilutive government funding, we are managing cash burn very carefully in order to achieve our near-term milestones. We continue to evaluate a number of strategic options, including but not limited to, partnership and merger and acquisition opportunities'.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.396 USD | +1.54% | +3.39% | -47.70% |
Apr. 25 | Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa | CI |
Apr. 15 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.70% | 5.55M | |
-1.17% | 102B | |
+2.87% | 96.09B | |
+2.13% | 22.28B | |
-14.77% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.21% | 16.09B | |
+8.55% | 13.83B | |
+35.75% | 11.97B |
- Stock Market
- Equities
- SNGX Stock
- News Soligenix, Inc.
- Soligenix Seeks Acquisitions